SOPHiA GENETICS Reports Third Quarter 2026 Results
<p>BOSTON and ROLLE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Revenue was $24.3 million,...</p>
Read original article ↗
Related Articles
In this free webinar, learn how advanced therapy supply chains can support global expansion without requiring major infr
Des millions d'employés collaborent quotidiennement sur Microsoft Teams, mais les contenus d'entreprise régis se trouven
Medrio Launches New CTMS as First Step Toward One Connected Clinical Trial Platform
Medrio CTMS, built for small and scaling sponsors and CROs, is available now through the Early Adopter Program ahead of
New headless capabilities let enterprises embed real-time guidance, automation, and after-call work directly into existi